Smith Jill D. 4

What Happened

• Jill D. Smith, a director of Evolent Health, was granted 41,096 restricted stock units (RSUs) on June 4, 2026. The award was reported as an acquisition at $0.00 per share (standard for RSUs); total purchase price reported is $0.
• This is a grants/compensation event (transaction code A), not a market purchase or sale.

Key Details

• Transaction date: June 4, 2026; Form 4 filed June 8, 2026 (timely under the 2-business-day rule).
• Shares/units granted: 41,096 RSUs; reported acquisition price: $0.00.
• Shares owned after transaction: Not specified in this filing.
• Footnotes:
  • F1: RSUs granted under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.
  • F2: RSUs vest on the earlier of June 4, 2027, and the date of the Company’s 2027 annual meeting, subject to Ms. Smith’s continued service on the vesting date.

Context

• RSUs are a form of equity compensation that convert to common shares upon vesting; they do not represent an immediate cash outlay or sale.
• Director grants are commonly routine compensation and do not, by themselves, signal a buying or selling decision by the insider.